Study Title
Prospective Phase 0 Pilot Study, Assessing Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients
Study Details
Description:
The goal of the study is to assess how [68Ga]Ga-PentixaFor is distributed in the body using PET/CT imaging. This will help demonstrate the potential of CXCR4 as a promising target for new treatments. If successful, [68Ga]Ga-PentixaFor PET/CT could become a valuable tool for identifying patients who might benefit from treatments using [177Lu]/[90Y] PentixaTher.
Sponsor:
Institut Cancerologie de l'Ouest
Contacts:
CAROLINE ROUSSEAU, MD, PhDcaroline.rousseau@ico.unicancer.fr
+33 2 40 67 99 31
NADIA ALLAM, PhDnadia.allam@ico.unicancer.fr
+33 2 40 67 98 26
Government Study Link:
NCT06962163 - Click here to see study onClinicalTrials.gov
Drug Details
[68Ga]Ga-Pentixafor
Isotope(s):
- GALLIUM-68
GALLIUM-68
Radioisotope: Ga-68
Theranostic Role: PET Imaging
T1/2 (Half-Life): 68 minutes
Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
Range: N/A
Decay Daughters: Zn68 (Stable)
Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
Target(s):
- CXCR4
Ligand: Small Molecules
Chelator: DOTA
